SOLESTA

Solesta™ is a product for effective treatment of fecal incontinence. Fecal incontinence is the lost ability to control gases and feces, for example. Around two percent of the population suffers from the problem, above all women due to damage incurred in connection with childbirth. The product was approved for sales in Europe at the end of 2006.

During 2009 the first part of a study was successfully completed that will form the basis of the application for product registration in the USA. The study achieved the objectives that had been set. More than 200 patients in thirteen different clinics in the USA and Europe participated in the study. Sales of Solesta amounted to 1 MSEK during the year.

During the second quarter of 2009 a transaction was carried out whereby Oceana Therapeutics acquired 100 percent of the shares in Q-Med Scandinavia Inc. Through the transaction Oceana Therapeutics obtained exclusive rights to globally commercialize the products Deflux and Solesta. The deal also comprised other products intended for the treatment of urological and gastroenterological conditions. Q-Med will continue to develop and manufacture all products included in the agreements. Q-Med received the first payment of 60 MUSD from Oceana Therapeutics in June 2009.

Oceana Therapeutics, Inc.
2035 Lincoln Highway
Edison, NJ 08817, USA
Tel: +1 732-318-3800
Fax: +1 732-318-3801
www.oceanathera.com

Email: info@oceanathera.com